Talis Biomedical Corp reports results for the quarter ended in September - Earnings Summary

Talis Biomedical

15/11/2021 23:16

* Talis Biomedical Corp  TLIS.OQ  reported a quarterly adjusted
loss of $1.49​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of $1.40 per share.
* Revenue was $218.00 thousand​;  analysts expected $1.46
million. 
* Talis Biomedical Corp's reported EPS for the quarter was a
loss of $1.49​.
* The mean earnings estimate of analysts had fallen by
about 6.5% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Talis Biomedical Corp shares had fallen by 9.4% this quarter.
* The company reported a quarterly loss of $38.42 million.
* Wall Street's median 12-month price target for Talis
Biomedical Corp is $7.00 
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 
This summary was machine generated November 15 at 11:16 p.m.
 ​All figures in US dollars unless otherwise stated